The United States Court of Appeals for the Federal Circuit has affirmed judgment in favour of Zydus Cadila’s US subsidiary, Zydus Pharmaceuticals (USA) Inc., holding that its proposed generic version of Lialda (Mesalamine) does not infringe U.S. Patent No. 6,773,720.
Lialda is indicated for the induction of remission of active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects around 700,000 people in the United States.
Zydus was the first pharmaceutical company to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda (Mesalamine). The Court of Appeals’ decision is a major step toward Zydus providing a generic version of Lialda (Mesalamine) in the United States. Shire has reported annual sales of $714 million for this product in 2016 in the United States.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1464.85 |
| Dr. Reddys Lab | 5955.65 |
| Cipla | 1477.15 |
| Zydus Lifesciences | 1050.35 |
| Lupin | 1603.55 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
